Acquisitions · Pharmaceuticals (cell therapy)
Astellas buys cell therapy company Xyphos for up to $665 million
- Buyer
- Astellas Pharma (Tokyo)
- Target
- Xyphos Biosciences, South San Francisco, California
- Value
- $120M upfront; up to $665M with milestones
- Status
- Agreed and completed in December 2019.
- Date
- 2019-12-26
Astellas Pharma bought Xyphos Biosciences, a South San Francisco company developing cell therapies for cancer, for $120 million upfront. Further payments tied to development milestones could bring the total to $665 million. The deal came weeks after Astellas agreed to buy Audentes.
Why it matters
Together with Audentes, the deal showed Astellas building up its US base in new treatment types such as gene and cell therapy.
Sources
Kakehashi M&A News home
